Mr. Adam Rogers reports

NERVGEN PHARMA ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER, BILL ADAMS

Bill Adams will retire as Nervgen Pharma Corp.'s chief financial officer, effective March 15, 2026. The company has engaged a leading executive search firm to identify a successor and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition.

"On behalf of the board of directors and our Nervgen employees, I want to thank Bill for his financial and strategic leadership, as well as extend our sincere gratitude for his unwavering dedication and commitment to the company," said Adam Rogers, MD, president and chief executive officer of Nervgen. "Bill joined us at a critical moment in the life cycle of the company six years ago and has been a trusted colleague and adviser. His integrity, thoughtfulness and commitment to our mission have been invaluable to me personally and to the entire organization. We're grateful for everything Bill has contributed to Nervgen and wish him the best in a well-deserved retirement."

"I am honoured to have served as chief financial officer of Nervgen and to have played a meaningful role in all that we've accomplished over the past several years," Mr. Adams commented. "It gives me great joy to have helped guide the company's dramatic transformation from preclinical and first-in-human studies to a Nasdaq-listed company entering late-stage development for NVG-291, a therapeutic candidate with the potential to significantly impact the lives of so many around the world living with spinal cord injury."

"These past six years at Nervgen has been unlike anything else I've had the opportunity to work on in my career, and I'm incredibly proud of the financial and operational foundation we've built. I believe the company is well positioned, with a clear path ahead. I look forward to supporting Nervgen during this transition and cheering on its continued success in the years to come," Mr. Adams concluded.

About Nervgen Pharma Corp.

Nervgen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The company's mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. Nervgen's lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide. NVG-291 was evaluated in the phase 1b/2a Connect SCI study in individuals with chronic SCI between one and 10 years postinjury, and is the first pharmacologic candidate to demonstrate durable improvement in function, independence and quality of life. The company's phase 1b/2a Connect SCI study in individuals with subacute SCI is continuing, alongside preparation for a phase 3 clinical trial in chronic SCI. NVG-291 has received fast-track designation from the U.S. Food and Drug Administration and orphan drug designation from the European Medicines Agency (EMA) for the treatment of SCI. Through NVG-291 and the company's next-generation candidate, NVG-300, Nervgen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.

We seek Safe Harbor.